Novo Plans to Seek US Approval for Its High-Dose Obesity Shot
-
最新报道：Novo Nordisk plans to seek FDA approval for a high-dose version of Wegovy, aiming to compete with Eli Lilly's Zepbound in the obesity market. Chief Scientific Officer Martin Holst Lange stated the high-dose option offers similar weight-loss potential, providing patients an alternative. The announcement was made at the European Association for the Study of Diabetes conference in Vienna.
下一篇
UK Stocks Are So Out of Favor They’re Now a Top Contrarian Trade
- Investors are increasingly bearish on UK stocks, with Bank of America strategists labeling...
24小时热点
热点专题
407106